How do cellular expression patterns differ between HLA Class I and Class II proteins? Assay Design Guide

A fundamental expression dichotomy defines the two HLA classes.
HLA Class I proteins (A, B, C) are present on virtually all nucleated cells and platelets, while Class II proteins (DR, DQ, DP) are constitutively limited to professional antigen‑presenting cells—though they can be induced on other cells during inflammation. This distinction directly dictates which antibodies must be detected in transplant and transfusion assays: platelet transfusion support requires Class I‑only antibody screening, but solid organ crossmatch demands simultaneous assessment of both classes to fully capture graft rejection risk.

The expression pattern of HLA proteins is the blueprint for diagnostic target selection. Because platelets express only Class I, assays for platelet‑transfusion refractoriness focus solely on anti‑Class I antibodies. In contrast, because all nucleated cells express Class I and activated cells can express Class II, organ transplant crossmatching must test for both.

The Cellular Landscape of HLA Expression

HLA Class I: The Ubiquitous Sentinel

Class I molecules (HLA‑A, HLA‑B, HLA‑C) are found on every nucleated cell in the body, from cardiomyocytes to renal tubular epithelium. They are also present on platelets, which inherit their membrane from megakaryocytes.

Expression levels are not uniform. HLA‑A and HLA‑B are expressed at high density, while HLA‑C is expressed at a markedly lower level—often only 10–20% of the A/B density. This gradient has direct consequences for antibody detection and diagnostic sensitivity.

HLA Class II: The Specialized Messenger

Class II molecules (HLA‑DR, HLA‑DQ, HLA‑DP) are constitutively expressed only on professional antigen‑presenting cells—B lymphocytes, monocytes/macrophages, and dendritic cells. Under basal conditions, most parenchymal cells and endothelial surfaces are Class II‑negative.

Critically, inflammatory cytokines (especially IFN‑γ) can up‑regulate Class II on many somatic cells. This means that in the context of infection, rejection, or tissue injury, a transplanted organ will display far more Class II than a healthy immunophenotype might suggest.

The Critical Exception: Platelet Expression

Platelets express abundant Class I but are completely devoid of Class II. This makes platelet transfusion uniquely vulnerable to anti‑Class I antibodies that trigger clearance and refractory states, while anti‑Class II antibodies are irrelevant in this compartment.

Translating Expression into Diagnostic Strategy

Platelet Transfusion Refractoriness: A Class I‑Only Problem

When a patient repeatedly fails to achieve a post‑transfusion platelet increment, anti‑HLA antibodies are a common cause. Because the target cell (the platelet) carries only Class I, assay design must focus on detecting antibodies against HLA‑A, HLA‑B, and HLA‑C.

Including Class II targets in a platelet‑refractoriness panel would add noise—detecting antibodies that cannot bind platelets—and waste valuable reagent real estate. The clinical question is narrow: “Is there an IgG antibody that will opsonize this donor’s platelets?” The assay must reflect that biology.

Solid Organ Transplant: The Dual‑Threat Environment

In a donor organ, endothelial cells and parenchymal cells constitutively express Class I, so an anti‑Class I antibody can bind immediately upon reperfusion. However, the graft also carries passenger antigen‑presenting cells that express Class II, and inflammation rapidly induces Class II on vascular endothelium.

Therefore, a crossmatch or antibody screen that tests only Class I will miss donor‑specific anti‑Class II antibodies—most notably anti‑DR and anti‑DQ—that are potent mediators of acute and chronic rejection. Full transplant compatibility assessment must interrogate both classes simultaneously.

The Impact of Expression Level: The HLA‑C Dilemma

Lower HLA‑C expression can create a silent risk. In complement‑dependent cytotoxicity (CDC) assays, anti‑HLA‑C antibodies may not trigger cell killing because the antigen density is below the threshold needed for complement activation. This can produce a false‑negative crossmatch.

Modern single‑antigen bead (SAB) assays overcome this by presenting purified Class I molecules at controlled densities. Nevertheless, diagnostic manufacturers must ensure that any assay targeting Class I has sufficient analytical sensitivity to detect low‑titer anti‑HLA‑C if the clinical goal is to avoid missed donor‑specific antibodies.

Diagnostic Pitfalls and Trade‑offs

Inducible Class II Can Skew Antibody Screening

If a cell‑based assay uses resting T cells (which are Class II‑negative) as the sole substrate, it will miss all anti‑Class II antibodies. This is the historical rationale for the “T‑cell/B‑cell crossmatch”: T cells serve as a pure Class I indicator, while isolated B cells (constitutively Class II‑positive) reveal Class II antibodies. Any single‑cell‑type strategy that ignores inducible expression risks false‑negative readouts in inflammatory environments.

Poor Expression of HLA‑C May Lead to False Security

Traditional lymphocytotoxicity panels often fail to detect anti‑HLA‑C antibodies, leading to unexplained platelet refractoriness or early graft dysfunction. Labs that rely solely on CDC without supplementary SAB or flow‑cytometric crossmatch may under‑identify clinically significant antibodies. The trade‑off is clear: simpler, faster assays may sacrifice the sensitivity needed to catch low‑expression targets.

Selecting the Appropriate Cellular Substrate

Manufacturers of diagnostic controls and kits must choose cell lines that faithfully mirror the in vivo target. For Class I‑only assays, nucleated cell lines or recombinant monomers loaded with β2‑microglobulin suffice. For Class II, B‑lymphoblastoid lines are the gold standard for surface expression; recombinant α/β heterodimers must be carefully refolded to present the correct conformational epitopes. Using the wrong substrate—such as a Class II antigen on a cell that never expresses it naturally—can generate antibodies that recognize non‑native structures and produce misleading results.

Making the Right Choice for Your Assay Platform

Your target antigen selection must be guided by the clinical question, not by assay convenience.

• If your primary focus is platelet transfusion support: Select only Class I HLA antigens (A, B, and C, with the caveat that HLA‑C detection may require enhanced sensitivity). Introducing Class II targets adds irrelevant complexity and risks misinterpreting results.
• If your primary focus is solid organ transplant compatibility: Mandate both Class I and Class II panels in crossmatch and antibody identification assays. Undetected donor‑specific Class II antibodies (especially anti‑DR and anti‑DQ) can cause acute rejection that a Class I‑only screen would never predict.
• If you are developing cellular substrates or recombinant controls: Ensure your Class I reagents represent the intact heavy chain/β2‑microglobulin complex at physiologic expression levels, and that your Class II reagents capture the native α/β heterodimer. For Class II‑specific detection, use B‑lymphocyte lines or co‑transfected cells to faithfully reproduce the restricted expression pattern seen in vivo.

By anchoring your assay design to the actual expression biology, you ensure that every diagnostic result directly answers the clinical question at hand.

Summary Table:

Accelerate Your HLA Assay Development with CamelBio

Designing accurate immunodiagnostic assays requires biologically faithful raw materials and robust platform strategies. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

Partner with us to optimize your target antigen selection, recombinant controls, and assay performance. Contact CamelBio today to learn how we can empower your diagnostic solutions.